Related Experiment Video

Updated: May 28, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Lapatinib in the treatment of HER-2 overexpressing breast cancer

E Vrdoljak1, M Boban, M Ban

  • 1Center of Oncology, Clinical Hospital Split, Split, Croatia. eduard.vrdoljak@st.t-com.hr

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|October 19, 2011
PubMed

Insights

Lapatinib is a key treatment for HER-2 positive cancers resistant to other therapies. Combining it with letrozole or trastuzumab shows significant benefits in specific patient groups.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lapatinib is a targeted therapy for HER-2 positive cancers.
  • It is used when initial treatments like trastuzumab fail.

Purpose of the Study:

  • To review the current clinical status of lapatinib.
  • To discuss future perspectives for lapatinib in cancer treatment.

Main Methods:

  • Literature review of clinical studies on lapatinib.
  • Analysis of data on lapatinib efficacy and safety.

Main Results:

  • Lapatinib is effective in HER-2 positive tumors progressing after trastuzumab, taxanes, and anthracyclines.
  • Combination with letrozole benefits postmenopausal patients with ER and HER-2 positive disease.
  • Neoadjuvant data supports trastuzumab and lapatinib combination for early HER-2 positive breast cancer.

Conclusions:

  • Lapatinib holds a significant place in managing advanced HER-2 positive cancers.
  • Its role is expanding, particularly in combination therapies and early-stage disease.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...